| scholarly article | Q13442814 |
| P50 | author | Peng Liu | Q88920249 |
| P2093 | author name string | Zhenyu Li | |
| Qing Deng | |||
| Hui Cao | |||
| Ting Yan | |||
| Kang Zheng | |||
| YongLi Hou | |||
| SiHai Hu | |||
| P2860 | cites work | Eliminating Factor H-Binding Activity of Borrelia burgdorferi CspZ Combined with Virus-Like Particle Conjugation Enhances Its Efficacy as a Lyme Disease Vaccine | Q50334209 |
| Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults | Q57793536 | ||
| A proof-of-concept study for the design of a VLP-based combinatorial HPV and placental malaria vaccine | Q63634603 | ||
| Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation | Q78852123 | ||
| Cyclooxygenase-2 inhibition attenuates antibody responses against human papillomavirus-like particles | Q79370189 | ||
| Role of Gonococcal Neisserial Surface Protein A (NspA) in Serum Resistance and Comparison of Its Factor H Binding Properties with Those of Its Meningococcal Counterpart | Q90227075 | ||
| Anti-Factor H Antibody Reactivity in Young Adults Vaccinated with a Meningococcal Serogroup B Vaccine Containing Factor H Binding Protein | Q91592664 | ||
| A preliminary study on the application of PspA as a carrier for group A meningococcal polysaccharide | Q91767900 | ||
| Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine | Q92705378 | ||
| Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults | Q93073290 | ||
| Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease | Q27028161 | ||
| Structural and Functional Correlates of Enhanced Antiviral Immunity Generated by Heteroclitic CD8 T Cell Epitopes | Q27683638 | ||
| The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism | Q28346519 | ||
| Intranasal vaccination with murabutide enhances humoral and mucosal immune responses to a virus-like particle vaccine | Q28728786 | ||
| Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes | Q33909134 | ||
| Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein. | Q34001933 | ||
| Zinc piracy as a mechanism of Neisseria meningitidis for evasion of nutritional immunity | Q35034259 | ||
| A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice | Q35181636 | ||
| Neisseria gonorrhoeae NspA induces specific bactericidal and opsonic antibodies in mice | Q35530224 | ||
| Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes | Q37279007 | ||
| On the mechanism determining the TH1/TH2 phenotype of an immune response, and its pertinence to strategies for the prevention, and treatment, of certain infectious diseases | Q38200691 | ||
| Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015. | Q38525922 | ||
| Prevention and control of meningococcal outbreaks: The emerging role of serogroup B meningococcal vaccines | Q38532922 | ||
| DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. | Q38877739 | ||
| Screen of multifunctional monoclonal antibodies against hepatitis B core virus-like particles | Q39843289 | ||
| High predicted strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in Poland | Q40189392 | ||
| Chimeric virus-like particles containing a conserved region of the G protein in combination with a single peptide of the M2 protein confer protection against respiratory syncytial virus infection | Q40684226 | ||
| Genetically engineered multi-component virus-like particles as veterinary vaccines | Q40795529 | ||
| Subunit Protein Vaccine Delivery System for Tuberculosis Based on Hepatitis B Virus Core VLP (HBc-VLP) Particles | Q40801602 | ||
| Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection | Q41966979 | ||
| Secreted proteins of Neisseria meningitidis protect mice against infection | Q44379794 | ||
| Chimeric hepatitis B virus core particles carrying an epitope of anthrax protective antigen induce protective immunity against Bacillus anthracis | Q45391150 | ||
| Dimorphism of hepatitis B virus capsids is strongly influenced by the C-terminus of the capsid protein | Q45770342 | ||
| Targeted lymph node immunization with simian immunodeficiency virus p27 antigen to elicit genital, rectal, and urinary immune responses in nonhuman primates. | Q45789762 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | Hepatitis B virus | Q6844 |
| Neisseria meningitidis | Q154625 | ||
| P304 | page(s) | 6601-6613 | |
| P577 | publication date | 2019-08-16 | |
| P1433 | published in | International Journal of Nanomedicine | Q6051502 |
| P1476 | title | Chimeric hepatitis B virus core particles displaying Neisserial surface protein A confer protection against virulent Neisseria meningitidis serogroup B in BALB/c mice | |
| P478 | volume | 14 |
Search more.